Welcome to our dedicated page for Arena Pharmaceuticals news (Ticker: ARNA), a resource for investors and traders seeking the latest updates and insights on Arena Pharmaceuticals stock.
This page provides a historical news archive for Arena Pharmaceuticals, Inc. (ARNA), a clinical-stage biopharmaceutical company that focused on developing investigational therapies for immuno-inflammatory and cardiovascular diseases. The news flow around ARNA captured key milestones in its clinical programs, corporate developments, and the definitive agreement under which Pfizer agreed to acquire Arena in an all-cash transaction.
Readers can review company-issued press releases covering progress in Arena’s gastroenterology, dermatology, and cardiology pipelines. These include updates on the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials of etrasimod in ulcerative colitis, the Phase 2/3 CULTIVATE program in Crohn’s disease, and Phase 2 studies of etrasimod in atopic dermatitis and alopecia areata. Additional news items describe Phase 2 development of cardiovascular assets temanogrel and APD418, as well as collaborations and option agreements related to other investigational compounds.
The archive also contains quarterly and annual financial result announcements, which detail Arena’s research and development spending, selling, general and administrative expenses, and net losses as it advanced its clinical-stage portfolio. Corporate governance and compensation-related releases, such as inducement grants under Nasdaq Listing Rule 5635(c)(4), provide further insight into Arena’s growth and hiring during its development phase.
Because Arena entered into an acquisition agreement with Pfizer, these news items primarily serve as historical context for ARNA rather than current standalone company updates. Investors, researchers, and students of the biopharmaceutical sector can use this record to trace how Arena communicated the evolution of its pipeline, its financial profile as a clinical-stage company, and the strategic rationale presented when Pfizer announced its plan to acquire Arena.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 17 new employees on July 16, 2021. A total of 45,200 stock options and 20,235 RSUs were issued, with stock options priced at $64.33 per share, equal to the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year, and the remaining 75% vesting monthly. The RSUs also have a four-year vesting schedule. This grant complies with Nasdaq Listing Rule 5635(c)(4).
Arena Pharmaceuticals (Nasdaq: ARNA) announced the appointment of Douglas J. Manion as Executive Vice President of Research & Development. Dr. Manion, who has over 20 years in the pharmaceutical industry, will report to Amit D. Munshi, President and CEO. His previous roles include CEO of Kleo Pharmaceuticals and Senior Vice President at Bristol-Myers Squibb. Arena has a diversified pipeline targeting gastroenterology, dermatology, and cardiology, including four investigational medicines across eight indications and eleven clinical trials.
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 17 new employees on June 15, 2021. The options allow for the purchase of 64,401 shares at an exercise price of $65.60, vesting over four years. Additionally, 27,857 RSUs were granted, also vesting over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) to attract new talent. The options and RSUs are part of Arena's 2021 Long-Term Incentive Plan.
Arena Pharmaceuticals (Nasdaq: ARNA) appointed Steven Schoch to its Board of Directors and as Chair of the Audit Committee. Schoch brings over 20 years of financial and operational leadership from biopharmaceuticals and media sectors. Previously, he served as Chief Financial Officer at 23andMe and held executive roles at Miramax and Amgen. Arena's leadership expressed optimism about Schoch's financial and strategic experience benefiting the company's growth plans as they advance a diversified portfolio targeting various therapeutic areas.
Arena Pharmaceuticals (Nasdaq: ARNA) announced that the FDA granted Orphan Drug Designation for etrasimod, a selective sphingosine 1-phosphate receptor modulator, for treating eosinophilic esophagitis (EoE). This drug is currently assessed in the Phase 2b VOYAGE trial, focusing on safety and efficacy in about 100 participants. The designation is significant as no FDA-approved therapies exist for EoE. Arena aims to bring this potential therapy to patients, highlighting its commitment to addressing unmet medical needs.
Arena Pharmaceuticals has initiated a Phase 2 trial for IV temanogrel, targeting coronary microvascular obstruction (cMVO) in patients undergoing percutaneous coronary intervention (PCI). With no FDA-approved treatments for cMVO, this trial aims to evaluate the safety and efficacy of temanogrel. The trial will enroll 99 participants across multiple countries, with a primary endpoint assessing changes in Index of Microcirculatory Resistance. Phase 2 results are anticipated in the latter half of 2022, marking a significant step in Arena's Cardiovascular Portfolio.
Summary not available.
Arena Pharmaceuticals (Nasdaq: ARNA) granted inducement stock options to 22 new employees on May 15, 2021. A total of 74,905 shares were authorized for stock options, alongside 32,050 restricted stock units (RSUs). The stock options, with an exercise price of $61.46 per share, vest over four years. The RSUs similarly vest over four years with a structured timeline. Both incentives are governed by Arena's Amended and Restated 2020 Long-Term Incentive Plan, highlighting Arena's commitment to attract talent and support employee retention.
Summary not available.
Arena Pharmaceuticals (Nasdaq: ARNA) reported its financial results for Q1 2021, revealing a net loss of $118.4 million, an increase from $100.2 million in Q1 2020. Revenues were nil, down from $0.3 million year-over-year. R&D expenses rose to $102.5 million, driven by clinical advancements, while SG&A expenses increased to $29.5 million. The company highlighted progress in its clinical pipeline, including full enrollment in the ELEVATE UC 52 Phase 3 study for etrasimod and the initiation of additional studies targeting eosinophilic esophagitis and ulcerative colitis.